Merck Serono, a division of Merck KGaA, has signed a five-year agreement with Kadimastem to use of its drug-screening platform to discover new oral drugs for the treatment of Multiple Sclerosis (MS). The system developed by Kadimastem uses human functional tissues produced industrially from pluripotent stem cells to search for potential new drugs. Existing MS treatments act by slowing down the loss of myelin-forming cells, but there is great interest in finding new medications that could repair...